LifeStance Health (LFST) EBITDA Margin (2020 - 2026)

LifeStance Health has disclosed EBITDA Margin across 7 years of filings, most recently posting 3.53% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 341.0% year-over-year to 3.53%; the TTM figure through Mar 2026 stood at 1.51% (up 446.0% YoY), while the FY2025 annual figure was 0.61%, up 531.0% from the prior year.
• EBITDA Margin rose to 3.53% in Q1 2026, from 3.05% in the prior quarter.
• Over the last five years, EBITDA Margin for LFST reached as high as 3.53% in Q1 2026 and fell as low as 32.8% in Q2 2022.
• The 5-year median for EBITDA Margin is 7.53% (2024), against an average of 10.81%.
• The widest YoY moves for EBITDA Margin: up 5336 bps in 2022, down 2462 bps in 2022.
• A 5-year view of EBITDA Margin shows it stood at 20.3% in 2022, then gained by 17 bps to 16.76% in 2023, then surged by 87 bps to 2.14% in 2024, then soared by 243 bps to 3.05% in 2025, then rose by 16 bps to 3.53% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 3.53%, 3.05%, and 0.2% for Q1 2026, Q4 2025, and Q3 2025 respectively.